Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

54 results about "Anti-diabetic Agent" patented technology

Any substance used to reduce hyperglycemia or treat disorders associated with diabetes. Based on their mechanism of action, this class of agents can be classified to the following groups: directly acting insulomimetics, which activates insulin receptors; indirectly acting insulinomimetics, which increase insulin release such as sulfonylureas or which potentiate the effect of insulin such as metformin; those act directly on the metabolism of glucose such as inhibitors of glucosidases and inhibitors of aldose reductase.

Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents

The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein R1 is H or CN; R2 is selected from CH2R5, CH2CH2R5 and C(R3)(R4)—X2—(CH2)aR5; R3 and R4 are each independently selected from H and Me; R5 is selected from CON(R6)(R7), N(R8)C(=0)R9, N(R8)C(═S)R9, N(R8)SO2R10 and N(R8)R10; R6 and R7 are each independently R11(CH2)b or together they are —(CH2)2-Z-(CH2)2— or CH2-o-C6H4-Z-CH2—; R8 is H or Me; R9 is selected from R11(CH2)b, R11(CH2)bO and N(R6)(R7); R10 is R11(CH2)b; R11 is selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; R12 is selected from H2NCH(R13)CO, H2NCH(R14)CONHCH(R15)CO, C(R16)═C(R17)COR18 and R19OCO; R13, R14 and R15 are selected from the side chains of the proteinaceous amino acids; R16 is selected from H, lower alkyl (C1-C6) and phenyl; R17 is selected from H and lower alkyl (C1-C6); R18 is selected from H, lower alkyl (C1-C6), OH, O-(lower alkyl (C1-C6)) and phenyl; R19 is selected from lower alkyl (C1-C6), optionally substituted phenyl and R20C(=0)OC(R21)(R22); R20, R21 and R22 are each independently selected from H and lower alkyl (C1-C6); Z is selected from a covalent bond, —(CH2)c—, —O—, —SOd— and —N(R10)—; X1 is S or CH2; X2 is O, S or CH2; a is 1, 2 or 3; b is 0-3; c is 1 or 2; and d is 0, 1 or 2.
Owner:FERRING BV

Combination therapy for the treatment of diabetes

The present invention relates to compositions comprising an anti-obesity agent and an anti-diabetic agent useful for the treatment of diabetes, diabetes associated with obesity and diabetes-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.
Owner:MERCK & CO INC +1

Curcumin combination with Anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control

Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy, retinopathy, nephropathy, pancreatitis or neoplasias; (ii) treat patients with diabetic disease status without symptomatic or pathologic evidence of associated sequelae but requiring better glycemic control than that offered by standard of care anti-diabetic; and (iii) patients with objective signs or symptoms of sequelae from diabetes of anti-diabetic drugs. One three-drug combination of the present invention includes a slow release PLGA-curcumin and an oral gliptin (DPP-4)-inhibitor or any incretin-mimetic and metformin.
Owner:SIGNPATH PHARMA INC

Novel cyclic benzimidazole derivatives useful as Anti-diabetic agents

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
Owner:METABASIS THERAPEUTICS INC +1

Dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents

The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein R1 is H or CN; R2 is selected from CH2R5, CH2CH2R5 and C(R3)(R4)—X2—(CH2)aR5; R3 and R4 are each independently selected from H and Me; R5 is selected from CON(R6)(R7), N(R8)C(═O)R9, N(R8)C(═S)R9, N(R8)SO2R10 and N(R8)R10; R6 and R7 are each independently R11(CH2)b or together they are —(CH2)2—Z—(CH2)2— or CH2—o—C6H4—Z—CH2—; R8 is H or Me; R9 is selected from R11(CH2)b, R11(CH2)bO and N(R6)(R7); R10 is R11(CH2)b; R11 is selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; R12 is selected from H2NCH(R13)CO, H2NCH(R14)CONHCH(R15)CO, C(R16)═C(R17)COR18 and R19OCO; R13, R14 and R15 are selected from the side chains of the proteinaceous amino acids; R16 is selected from H, lower alkyl (C1–C6) and phenyl; R17 is selected from H and lower alkyl (C1–C6); R18 is selected from H, lower alkyl (C1–C6), OH, O-(lower alkyl (C1–C6)) and phenyl; R19 is selected from lower alkyl (C1–C6), optionally substituted phenyl and R20C(═O)OC(R21)(R22); R20, R21 and R22 are each independently selected from H and lower alkyl (C1–C6); Z is selected from a covalent bond, —(CH2)c—, —O—, —SOd— and —N(R10)—; X1 is S or CH2; X2 is O, S or CH2; a is 1, 2 or 3; b is 0–3; c is 1 or 2; and d is 0, 1 or 2.
Owner:FERRING BV

Method for enhancing insulin secretion

InactiveUS20080255031A1Reducing amount and frequencyReduces adverse eventsOrganic active ingredientsPeptide/protein ingredientsEnantiomerRanolazine
The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent.
Owner:CV THERAPEUTICS INC

Ranolazine for enhancing insulin secretion

The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent.
Owner:GILEAD PALO ALTO

Novel antidiabetic furostanolic saponin rich (FSR) fraction from fenugreek seeds

InactiveUS20120071427A1Effective treatmentEasily and conveniently formulatedBiocideOrganic active ingredientsOral treatmentAdditive ingredient
The present invention discloses a novel anti-diabetic composition extracted from fenugreek seeds. The same comprises a furostanolic-saponin-rich fraction (>70%) with approximately 30% protodioscin as one of the bioactive components. Pre-clinical studies in rats indicated significant glucose lowering effect of the fraction (31.5%) as compared to control after two weeks of oral treatment. Clinical studies in human volunteers indicated suitability of a dosage form of 500 mg given once or twice daily as anti-diabetic agent either alone or in combination with standard, synthetic anti-diabetic drugs such as metformin and glipizide in controlling plasma glucose levels.
Owner:GOEL PAWAN KUMAR

Treatment of diabetes and associated metabolic conditions with epigenetic modulators

The present invention describes small molecules that have the activity of directly enhancing insulin sensitivity through epigenetic regulation. These small molecules, therefore, provide a new path for the treatment of type 2 diabetes and insulin resistance in type 1 diabetes or prediabetes and also can be used to treat obesity and chronic liver disease. Methods and compositions including these small molecules or for their administration are described. The methods and compositions can include additional anti-diabetic agents.
Owner:TEMPLE OTORONGO LLC

Halide-free glucosamine-acidic drug complexes

A complex of glucosamine having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and a therapeutic drug having a pKa of less than 7. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and / or water-swellable homopolymer and / or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers, povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated complex will be stable upon exposure to ambient temperature and / or the atmosphere. Suitable therapeutic drugs fall into the following classes: α- and β-Adrenergic Agonists; Narcotic and Non-Narcotic Analgesics; Anorexics; Antiallergics; Antianginals; Antiarrhythmics; Antiasthmatics; Antibiotics; Anticoagulants; Anticonvulsants; Antidepressants; Antidiabetics; Antihistaminics; Antihypertensives; Nonsteroidal Anti-Inflammatories; Antimigraines; Antineoplastics; Antiparkinsonians; Antipsychotics; Antipyretics; Antispasmodics; Antithrombotics; Antiulceratives; Anxiolytics; Decongestants; Diuretics; Hepatoprotectants; Sedatives; and Vasodilators.
Owner:GLUCONOVA

Novel diphenylethylene compounds

Novel diphenylethylene and styrenes are provided which are administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulienmic and hypertriglycedmic rats. The compounds are orally effective anti-diabetic agents that potentially may reduce abnormality of glucose and lipid metabolism in diabetes.
Owner:CALYX THERAPEUTICS

Novel cyclic benzimidazole derivatives useful Anti-diabetic agents

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
Owner:MERCK SHARP & DOHME LLC

Cyclic benzimidazole derivatives useful as anti-diabetic agents

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
Owner:METABASIS THERAPEUTICS INC +1

Pdia4 protein as a target for diagnosis, monitoring and treatment of diabetes

ActiveUS20170049794A1Aggravates diabetes developmentReverse diabetesOrganic active ingredientsCompound screeningDiabetes-Related ComplicationsCombination therapy
A Pdia4 inhibitor for use in preventing, alleviating and / or treating diabetes and / or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and / or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and / or an anti-diabetic agent.
Owner:ACAD SINIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products